This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Summary
Atracurium is a neuromuscular blocker indicated to relax muscles during mechanical ventilation under general anesthesia or intubation.
- Generic Name
- Atracurium
- DrugBank Accession Number
- DB13295
- Background
Not Available
- Type
- Small Molecule
- Groups
- Approved, Experimental, Investigational
- Synonyms
- Not Available
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your software1,2-Benzodiazepine The risk or severity of CNS depression can be increased when 1,2-Benzodiazepine is combined with Atracurium. Acetazolamide The risk or severity of CNS depression can be increased when Acetazolamide is combined with Atracurium. Acetophenazine The risk or severity of CNS depression can be increased when Acetophenazine is combined with Atracurium. Acetyldigitoxin The risk or severity of Cardiac Arrhythmia can be increased when Atracurium is combined with Acetyldigitoxin. Aclidinium The risk or severity of adverse effects can be increased when Aclidinium is combined with Atracurium. Agomelatine The risk or severity of CNS depression can be increased when Agomelatine is combined with Atracurium. Alfentanil The risk or severity of adverse effects can be increased when Atracurium is combined with Alfentanil. Alimemazine The risk or severity of CNS depression can be increased when Alimemazine is combined with Atracurium. Alloin The therapeutic efficacy of Alloin can be decreased when used in combination with Atracurium. Almotriptan The risk or severity of CNS depression can be increased when Almotriptan is combined with Atracurium. 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
Categories
- ATC Codes
- M03AC04 — Atracurium
- Drug Categories
- Anticholinergic Agents
- Benzylisoquinolines
- Central Nervous System Depressants
- Cholinergic Agents
- Heterocyclic Compounds, Fused-Ring
- Isoquinolines
- Muscle Relaxants
- Muscle Relaxants, Peripherally Acting Agents
- Musculo-Skeletal System
- Neuromuscular Agents
- Neuromuscular Blocking Agents
- Neuromuscular Nondepolarizing Blockade
- Neuromuscular-Blocking Agents (Nondepolarizing)
- Neurotransmitter Agents
- Nicotinic Antagonists
- Peripheral Nervous System Agents
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 2GQ1IRY63P
- CAS number
- 64228-79-1
- InChI Key
- Not Available
- InChI
- Not Available
- IUPAC Name
- Not Available
- SMILES
- Not Available
References
- General References
- TITCK Product Information: Neucurium (atracurium besylate) solution for injection [Link]
- External Links
- 1218
- Wikipedia
- Atracurium_besilate
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Completed Diagnostic Atracurium / Cefazolin / Morphine / Nadroparin / Obesity 1 4 Completed Prevention Analgesia / Functional Endoscopic Sinus Surgery (FESS) / Premedication 1 4 Completed Prevention Kidney Diseases / Prostate Hypertrophy 1 4 Completed Supportive Care Post Operative Nausea and Vomiting (PONV) / Postoperative pain 1 4 Completed Supportive Care Quality of Ocular Akinesia (Onset and Duration) 1 4 Completed Treatment Neuromuscular Blockade / Regional Anesthesia therapy 1 4 Completed Treatment Tracheal Intubation 1 4 Unknown Status Other Patients Undergoing Laparoscopic Surgery 1 4 Unknown Status Treatment Anesthesia therapy 1 4 Unknown Status Treatment Myoclonus 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Solution Intravenous 50 mg Injection, solution Intravenous Injection Intravenous 25 mg/2.5ml Injection Intravenous 50 mg/5ml Injection Intravenous Injection, solution Intravenous 25 MG/2.5ML Injection, solution Intravenous 50 MG/5ML - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
- Not Available
- Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
Drug created at June 23, 2017 20:39 / Updated at June 02, 2021 20:03